Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 1

Interventions

Cyclophosphamide 518Bevacizumab 488Carboplatin 424pembrolizumab 389Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 317Radiotherapy 296Nivolumab 247Doxorubicin 244Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171Prednisone 167fludarabine 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has results × ferumoxtran-10 × Clear all
NCT00659334 2022-12-21

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

OHSU Knight Cancer Institute

Phase 2 Terminated
116 enrolled 12 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡